Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 21:15:1394997.
doi: 10.3389/fphar.2024.1394997. eCollection 2024.

Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies

Mohamed Tawengi #  1 , Yazan Al-Dali #  1 , Abdelaziz Tawengi #  1 , Ibrahim F Benter  2 , Saghir Akhtar  1
Affiliations
Review

Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies

Mohamed Tawengi et al. Front Pharmacol. .

Abstract

Epidermal growth factor receptor (EGFR), which is referred to as ErbB1/HER1, is the prototype of the EGFR family of receptor tyrosine kinases which also comprises ErbB2 (Neu, HER2), ErbB3 (HER3), and ErbB4 (HER4). EGFR, along with other ErbBs, is expressed in the kidney tubules and is physiologically involved in nephrogenesis and tissue repair, mainly following acute kidney injury. However, its sustained activation is linked to several kidney pathologies, including diabetic nephropathy, hypertensive nephropathy, glomerulonephritis, chronic kidney disease, and renal fibrosis. This review aims to provide a summary of the recent findings regarding the consequences of EGFR activation in several key renal pathologies. We also discuss the potential interplay between EGFR and the reno-protective angiotensin-(1-7) (Ang-(1-7), a heptapeptide member of the renin-angiotensin-aldosterone system that counter-regulates the actions of angiotensin II. Ang-(1-7)-mediated inhibition of EGFR transactivation might represent a potential mechanism of action for its renoprotection. Our review suggests that there is a significant body of evidence supporting the potential inhibition of EGFR/ErbB, and/or administration of Ang-(1-7), as potential novel therapeutic strategies in the treatment of renal pathologies. Thus, EGFR inhibitors such as Gefitinib and Erlinotib that have an acceptable safety profile and have been clinically used in cancer chemotherapy since their FDA approval in the early 2000s, might be considered for repurposing in the treatment of renal pathologies.

Keywords: ErbB; acute kidney injury (AKI); chronic kidney disease; diabetic nephropathy; epidermal growth factor receptor; glomerulonephritis; hypertensive nephropathy; renal fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The arrangement and cognate ligands of the ErbB family of receptors. An ErbB receptor is composed of an extracellular domain that binds specific ligands, a transcellular component, and an intracellular domain with a tyrosine kinase activity (TK). The ErbB-2 is not known to have any ligand, while the ErbB-3 is known to lack kinase activity. Once a ligand binds the extracellular domain of ErbB receptors, it induces dimerization of the receptor (homodimerization or heterodimerization), tyrosine kinase activation (TK), trans-phosphorylation (P) and initiation of downstream signaling cascades (see main text for further details).
FIGURE 2
FIGURE 2
Distribution of ErbB family of receptors (in black text) with their corresponding ligands (in blue text) throughout the nephron. The different receptors and their ligands are differentially expressed along the various segments of the nephron (including the glomerulus, proximal convoluted tubule, loop of Henle, distal convoluted tubule, and the collecting duct) in a human adult kidney. Note the exception: HB-EGF expression data is from rat kidneys (asterisked).
See this image and copyright information in PMC

References

    1. Abourehab M. A. S., Alqahtani A. M., Youssif B. G. M., Gouda A. M. (2021). Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules 26 (21), 6677. 10.3390/molecules26216677 - DOI - PMC - PubMed
    1. Akhtar S., Benter I. F. (2013). The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. Bioimpacts 3 (1), 5–9. 10.5681/bi.2013.008 - DOI - PMC - PubMed
    1. Akhtar S., Benter I. F., Danjuma M. I., Doi S. A. R., Hasan S. S., Habib A. M. (2020). Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. J. Drug Target 28 (7-8), 683–699. 10.1080/1061186X.2020.1797754 - DOI - PubMed
    1. Akhtar S., Chandrasekhar B., Attur S., Dhaunsi G. S., Yousif M. H., Benter I. F. (2015). Transactivation of ErbB family of receptor tyrosine kinases is inhibited by angiotensin-(1-7) via its mas receptor. PLoS One 10 (11), e0141657. 10.1371/journal.pone.0141657 - DOI - PMC - PubMed
    1. Akhtar S., Chandrasekhar B., Yousif M. H., Renno W., Benter I. F., El-Hashim A. Z. (2019). Chronic administration of nano-sized PAMAM dendrimers in vivo inhibits EGFR-ERK1/2-ROCK signaling pathway and attenuates diabetes-induced vascular remodeling and dysfunction. Nanomedicine 18, 78–89. 10.1016/j.nano.2019.02.012 - DOI - PubMed

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Funding for research in the laboratory of SA was provided by Qatar University grant QUCG-CMED-22/23-540.

LinkOut - more resources